With a strong foundation in investment banking, Emery J. Levick has established himself as a prominent player in corporate finance and strategic advisory. He co-founded a boutique investment firm focused on helping mid-market companies navigate complex transactions, mergers, and capital raises. His extensive experience spans multiple sectors including technology and healthcare, where he has successfully facilitated significant partnerships and investments. Known for his analytical acumen, Levick provides invaluable insights that drive value creation for clients during critical growth phases. As an active contributor to the evolving landscape of finance, his expertise positions him as a vital asset within the capital markets ecosystem.
With a strong foundation in investment banking, Emery J. Levick has established himself as a prominent player in corporate finance and strategic advisory. He co-founded a boutique investment firm focused on helping mid-market companies navigate complex transactions, mergers, and capital raises. His extensive experience spans multiple sectors including technology and healthcare, where he has successfully facilitated significant partnerships and investments. Known for his analytical acumen, Levick provides invaluable insights that drive value creation for clients during critical growth phases. As an active contributor to the evolving landscape of finance, his expertise positions him as a vital asset within the capital markets ecosystem.
Emery J. Levick operates at the intersection of strategic advisory and corporate finance, leveraging his extensive investment banking background to capitalize on emerging opportunities. His focus centers on mid-market firms undergoing transformative growth phases, where adept navigation of complex capital structures is essential. Emphasizing a proactive approach to deal-making, he identifies partnerships that drive synergies within technology and healthcare sectors. Through incisive analysis and hands-on guidance, Levick empowers clients to enhance their competitive positioning while executing well-timed financial maneuvers. His ability to cultivate value through nuanced understanding distinguishes him as a leading figure in advisory circles.
Emery J. Levick operates at the intersection of strategic advisory and corporate finance, leveraging his extensive investment banking background to capitalize on emerging opportunities. His focus centers on mid-market firms undergoing transformative growth phases, where adept navigation of complex capital structures is essential. Emphasizing a proactive approach to deal-making, he identifies partnerships that drive synergies within technology and healthcare sectors. Through incisive analysis and hands-on guidance, Levick empowers clients to enhance their competitive positioning while executing well-timed financial maneuvers. His ability to cultivate value through nuanced understanding distinguishes him as a leading figure in advisory circles.
| Trades 2077 | Longs Won 1296/2077 62% | Profit Factor 9 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $302,655.05 |
| Average Win $46,435.26 | Best Trade (Sep 04) $9.95M | Sharpe Ratio -501.71 |
| Average Loss -$8,562.7 | Worst Trade (Sep 14) -$623,660.47 | Z-Score -10.91 (100%) |
| Commissions $0 | Avg. Trade Length 2y 1m 2w 4d | Expectancy $25,754.76 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.17% |
| Consecutive Losing Trades | 12,658 | 11,392 | 10,127 | 8,861 | 7,595 | 6,329 | 5,063 | 3,797 | 2,532 | 1,266 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 0020 00206R102 | 18,186 | $491.61 | $527.21 | - | $35.6 | 7.24% | 0.0 |
| 0028 00287Y109 | 3,842 | $428.18 | $966.8 | - | $538.62 | 125.79% | 0.0 |
| 0207 02079K107 | 7,806 | $715.69 | $2,758.09 | - | $2,042.4 | 285.37% | 0.0 |
| 0207 02079K305 | 21,774 | $1,920.82 | $7,781.37 | - | $5,860.55 | 305.11% | 0.0 |
| 0302 03027X100 | 3,455 | $917.09 | $596.26 | - | -$320.83 | -34.98% | 0.0 |
| 0307 03076C106 | 1,938 | $513.29 | $889.08 | - | $375.79 | 73.21% | 0.0 |
| 0462 04621X108 | 3,787 | $598.33 | $824.85 | - | $226.52 | 37.86% | 0.0 |
| 1727 17275R102 | 13,919 | $760.64 | $1,634.93 | - | $874.29 | 114.94% | 0.0 |
| 2082 20825C104 | 4,535 | $315.99 | $471.46 | - | $155.47 | 49.2% | 0.0 |
| 3814 38141G104 | 2,233 | $844.58 | $1,889.1 | - | $1,044.52 | 123.67% | 0.0 |
| 5526 55261F104 | 2,170 | $325.36 | $516.48 | - | $191.12 | 58.74% | 0.0 |
| 5763 57636Q104 | 1,219 | $423.69 | $609.09 | - | $185.4 | 43.76% | 0.0 |
| 5893 58933Y105 | 7,277 | $546.86 | $875.35 | - | $328.49 | 60.07% | 0.0 |
| 6838 68389X105 | 8,103 | $706.47 | $1,187.5 | - | $481.03 | 68.09% | 0.0 |
| 7414 74144T108 | 3,904 | $768.16 | $351.91 | - | -$416.25 | -54.19% | 0.0 |
| 9132 91324P102 | 3,477 | $1,361.27 | $1,445.15 | - | $83.88 | 6.16% | 0.0 |
| 9282 92826C839 | 6,500 | $1,451.91 | $2,230.09 | - | $778.18 | 53.6% | 0.0 |
AAPL Apple Inc. | 36,364 | $5.15M | $12.27M | - | $7.12M | 138.29% | -0.721% |
ABT Abbott Laboratories | 3,682 | $422,694.88 | $380,037.63 | - | -$42,657.25 | -10.09% | -0.496% |
ADI Analog Devices, Inc. | 6,284 | $1.12M | $2.4M | - | $1.28M | 114.66% | -2.072% |